Book Description
This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on June 1, 2004. The length of the article is 570 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation Details
Title: FDA is cracking down on manufacturers of 'andro'.(Across Specialties)(Food and Drug Administration)
Author: Nancy Walsh
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: June 1, 2004
Publisher: International Medical News Group
Volume: 32 Issue: 6 Page: 81(1)Distributed by Thompson Gale
Excerpt. © Reprinted by permission. All rights reserved.
The Food and Drug Administration has begun a crackdown on companies that manufacture, market, and distribute products containing androstenedione, commonly known as "andro."
The first step the FDA took was to send warning letters to 23 companies asking them to cease distributing the products, and threatening enforcement actions such as seizures and injunctions if they fail to do so.
"We took this action because FDA has concluded that there is inadequate information to establish that these products marketed as dietary supplements would reasonably be expected to be safe," Dr. Susan Walker said in a press briefing sponsored by the FDA.
Home
